These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6805972)

  • 1. Mitomycin-C, VP16-213 combination as third line chemotherapy in advanced breast cancer.
    Perez Manga G; Madrigal Alonso PL; Alburquerque Carbuccia H
    Cancer Chemother Pharmacol; 1982; 7(2-3):227-9. PubMed ID: 6805972
    [No Abstract]   [Full Text] [Related]  

  • 2. Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.
    Perez Manga G; Madrigal Alonso P; Alburquerque Carbuccia H
    Cancer Chemother Pharmacol; 1982; 7(2-3):231-3. PubMed ID: 6896298
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.
    Schell FC; Yap HY; Hortobagyi GN; Issell B; Esparza L
    Cancer Chemother Pharmacol; 1982; 7(2-3):223-5. PubMed ID: 7083463
    [No Abstract]   [Full Text] [Related]  

  • 4. Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.
    Gutierrez ML; Crooke ST
    Cancer Treat Rev; 1979 Sep; 6(3):153-64. PubMed ID: 394834
    [No Abstract]   [Full Text] [Related]  

  • 5. VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.
    Estapé J; Cirera L; Millá A; Doncel F
    Cancer Chemother Pharmacol; 1983; 10(3):154-7. PubMed ID: 6861258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide in the treatment of refractory breast cancer.
    Höffken K
    Cancer Treat Rev; 1982 Jun; 9 Suppl():63-6. PubMed ID: 7127336
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
    Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
    Cancer Treat Rep; 1976 May; 60(5):633-5. PubMed ID: 1036468
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
    Dees A; Verweij J; van Putten WL; Stoter G
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1343-7. PubMed ID: 3119346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy.
    Lopez M; Papaldo P; Di Lauro L; Barduagni M; Perno CF; Barduagni A
    Oncology; 1983; 40(4):244-7. PubMed ID: 6408547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VP16-213 combined with cis-platinum (CDDP) in the treatment of small cell carcinoma of the lung (SCLC).
    Madrigal PA; Manga GP; Palomero I; Gomez RG
    Cancer Chemother Pharmacol; 1982; 7(2-3):203-4. PubMed ID: 6282485
    [No Abstract]   [Full Text] [Related]  

  • 11. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy.
    Buzdar AU; Tashima CK; Blumenschein GR; Hortobagyi GN; Yap HY; Krutchik AN; Bodey GP; Livingston RB
    Cancer; 1978 Feb; 41(2):392-5. PubMed ID: 630529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy.
    Harper PG; Dally MB; Geddes DM; Spiro SG; Smyth JF; Souhami RL
    Cancer Chemother Pharmacol; 1982; 7(2-3):179-80. PubMed ID: 6282480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)].
    Pouillart P; Palangie T; Jouve M; Garcia-Giralt E; Magdelenat H
    Nouv Presse Med; 1979 Aug 25-Sep 3; 8(33):2690. PubMed ID: 493073
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer.
    Eagan RT; Ahmann DL; Bisel HF
    Oncology; 1976; 33(3):146-8. PubMed ID: 1012648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)].
    Pouillart P; Palangie T; Jouve M; Garcia-Giralt E; Magdelenat H
    Bull Cancer; 1979; 66(5):485-90. PubMed ID: 554673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine.
    Sedlacek SM
    Oncology; 1993 Apr; 50 Suppl 1():16-21. PubMed ID: 8483557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy.
    Pasterz RB; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Cancer; 1985 Nov; 56(10):2381-4. PubMed ID: 4042070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin C and vinblastine chemotherapy for advanced breast cancer.
    Konits PH; Aisner J; van Echo DA; Lichtenfeld K; Wiernik PH
    Cancer; 1981 Sep; 48(6):1295-8. PubMed ID: 6791808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.
    Tempero M; Kessinger A; Lemon HM
    Cancer Clin Trials; 1981; 4(2):155-7. PubMed ID: 6265110
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer.
    Mattsson W; von Eyben F; Hallsten L; Bjelkengren G
    Cancer; 1982 Jan; 49(2):217-20. PubMed ID: 6797721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.